
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines demonstrated strong financial performance in 2024, ending the year with US$2.6 billion in cash and reporting Brukinsa sales of US$2.6 billion, reflecting a remarkable 105% year-over-year increase. In addition, Tevimbra sales grew by 16% year-over-year to US$621 million, surpassing competitor Innovent’s Tyvyt sales, showcasing BeOne's competitive edge within the oncology therapeutics market. Furthermore, analysts have increased their revenue forecasts for 2025 through 2027 by 9.6% to 12.5%, driven by the robust sales momentum of Brukinsa, which has overtaken its rival Calquence in both revenue and market share.
Bears say
BeOne Medicines is currently facing significant financial challenges, highlighted by a net loss of $645 million in the most recent reporting period, despite a narrowing loss year-over-year. The company's revenue outlook appears bleak, with a revised peak sales estimate for its key drug, Tevimbra, reduced from $2 billion to $1.5 billion by 2035 and a substantial cut to the ociperlimab peak sales estimate from $342 million to $172 million. Additionally, the potential for further downside is exacerbated by concerns regarding the efficacy of ongoing clinical trials, which presents binary risks if results do not show significant benefits.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares